Lava Therapeutics NV
Market Movers (8-K)
LAVA Therapeutics N.V. has been acquired by XOMA Royalty Corporation for $1.04 per share plus a contingent value right, with 91.1% of shares tendered.
LAVA Therapeutics N.V. announced the successful completion of XOMA Royalty Corporation's tender offer, leading to its delisting from Nasdaq and a change in company control.
LAVA Therapeutics N.V. shareholders overwhelmingly approved a proposed merger with LAVA Therapeutics New Topco B.V. and the appointment of new executive and non-executive directors at an Extraordinary General Meeting.
Capital raise
LAVA Therapeutics and XOMA Royalty amend their acquisition agreement, reducing the cash offer per share but lowering the minimum net cash condition and extending the tender offer.
Worse than expected
Delay expected
XOMA Royalty Corporation has extended its tender offer to acquire all outstanding common shares of LAVA Therapeutics N.V. until October 17, 2025.
Delay expected
Worse than expected
LAVA Therapeutics has postponed its Extraordinary General Meeting to early November 2025 to further discuss transaction terms with XOMA Royalty Corporation.
Worse than expected
Delay expected
Quarterly Earnings (10-Q)
LAVA Therapeutics N.V. reported Q3 2025 results, highlighting progress on its acquisition by XOMA Royalty Corporation, significant workforce reductions, and the discontinuation of clinical programs LAVA-1207 and LAVA-1266.
Delay expected
Worse than expected
LAVA Therapeutics N.V. announced a definitive agreement to be acquired by XOMA Royalty Corporation for $1.16 per share plus contingent value rights, alongside significant restructuring and program discontinuations.
Capital raise
Worse than expected
LAVA Therapeutics reports a net loss of $3.479 million for Q1 2025, but benefits from a $5.2 million gain on debt extinguishment and continues its strategic review process.
Worse than expected
Capital raise
Annual Reports (10-K)
LAVA Therapeutics, a clinical-stage immuno-oncology company, announces its 2024 financial results and a strategic review aimed at extending capital resources.
Worse than expected
Insider Trading (Form 4)
LAVA Therapeutics NV's Chief Financial Officer, Fred M. Powell, disposed of 65,000 common shares and cancelled 124,700 share options as part of a pre-arranged purchase agreement.
Capital raise
LAVA Therapeutics director Mary E. Wadlinger canceled 33,390 share options in exchange for cash and contingent value rights as part of a Purchase Agreement.
LAVA Therapeutics director Christy J. Oliger reported the cancellation of 33,390 share options in exchange for cash and contingent value rights.
LAVA Therapeutics Director James Noble cancels 33,390 share options for cash and contingent value rights.
LAVA Therapeutics Director Peter A. Kiener cancelled 33,390 share options, exchanging them for cash and contingent value rights as part of a pre-arranged plan.
LAVA Therapeutics NV Director Jay T. Backstrom cancelled 33,390 share options in exchange for cash and contingent value rights as part of a purchase agreement.
Proxy Statements (Def-14A)
LAVA Therapeutics N.V. shareholders are invited to an Extraordinary General Meeting on November 7, 2025, to vote on XOMA Royalty Corporation's amended tender offer of $1.04 cash plus one Contingent Value Right per share.
Worse than expected
Delay expected
LAVA Therapeutics and XOMA Royalty amend their share purchase agreement, reducing the cash per share to $1.04 and adjusting contingent value rights, while extending the tender offer and reconvening the EGM.
Delay expected
Worse than expected
XOMA Royalty Corporation and LAVA Therapeutics N.V. announced the extension of the tender offer for LAVA's outstanding shares until October 17, 2025.
Delay expected
LAVA Therapeutics N.V. has cancelled its Extraordinary General Meeting to approve the XOMA Royalty Corporation acquisition, rescheduling it for early November 2025 to finalize transaction terms.
Worse than expected
Delay expected
LAVA Therapeutics N.V. shareholders are invited to an Extraordinary General Meeting to vote on XOMA Royalty Corporation's offer to acquire all outstanding shares for cash and contingent value rights, a deal unanimously recommended by LAVA's Board.
Better than expected
XOMA Royalty Corporation has commenced a tender offer to acquire LAVA Therapeutics N.V. for $1.16 to $1.24 per share plus a contingent value right.
Schedule 13D - Activist Investments
Gilde Healthcare has reduced its beneficial ownership in LAVA Therapeutics N.V. to 3.9% after selling over 1.9 million common shares.
Worse than expected
Gilde Healthcare has significantly reduced its beneficial ownership in LAVA Therapeutics N.V. by selling over 2.2 million common shares in open market transactions.
Worse than expected
Gilde Healthcare, a significant shareholder, has sold 174,678 common shares of LAVA Therapeutics N.V. in open market transactions, reducing its beneficial ownership to 19.9%.
Worse than expected
Versant Venture Capital and related entities have fully divested their stake in LAVA Therapeutics N.V., selling over 2.9 million shares for approximately $4.07 million.
Worse than expected
Versant Venture Capital and Vantage funds have significantly reduced their beneficial ownership in LAVA Therapeutics N.V. through recent share sales totaling over $2.5 million.
Worse than expected
Schedule 13G - Passive Investments
Shay Capital LLC and Shay Capital Holdings LLC have reported a 9.9% beneficial ownership stake in LAVA Therapeutics NV, totaling 2,596,403 common shares.
BML Investment Partners, L.P. has reported a 7.4% beneficial ownership stake in LAVA Therapeutics N.V., holding 1,958,110 common shares.